Phase-I-trial approved for novel stem cell therapy for patients with ischemic cardiomyopathy
Viscofan BioEngineering advances collagenous carrier material as their first medical product to clinical development.
Download press release
Disclosure of R&D expenses in 2017
As part of its business development strategy, Viscofan BioEngineering pursues sustainable investments in biomedical research collaborations with public centers. According to the transparency rules established by EFPIA for the biopharmaceutic industry, Viscofan BioEngineering discloses annually the R&D expenses performed with public centers.
In 2017, Viscofan BioEngineering spent 88.000 € for the development of its product pipeline in regenerative medicine in joint projects with university and clinics which was backed by an additional 138.000€ in public funding.
Meet us at Vitafoods 2018
Presenting the premium collagen hydrolysate COLLinstant®, Viscofan BioEngineering welcomes the nutraceutical industry at booth # I103 at the Vitafoods 2018 in Geneva. Learn more about COLLinstant® and its numerous applications in the food sector and collect a free sample.
Collagen applications in the food industry
Viscofan BioEngineering portraits the increasing use of collagen as a nutraceutical and explains the advantages of COLLinstant® in a current blog on "Vitafoods Insight".
Presentation at the BioRN Annual Conference
Within the framework of the BioRN Annual Conference 2017: “Revolution through convolution – combining medtech, biotech and digital health to promote health science in our region”, corporate manager Dr. Lluís Quintana gave a talk entitled: „Viscofan BioEngineering – von der Wursthülle zum Medizinprodukt – from sausage casing to medical device“.
„Viscofan BioEngineering celebrates new GMP-facility with opening ceremony“
Download Press Release